{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:58:12Z","timestamp":1785164292127,"version":"3.55.0"},"reference-count":104,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,9,14]],"date-time":"2018-09-14T00:00:00Z","timestamp":1536883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["ID\u20109243"],"award-info":[{"award-number":["ID\u20109243"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p><jats:bold>Background<\/jats:bold>: Levodopa remains the gold\u2010standard treatment for PD. However, it becomes less effective as the disease progresses and produces debilitating side effects, such as motor fluctuations and <jats:sc>l<\/jats:sc>\u2010dopa\u2010induced dyskinesia. Modulation of metabotropic glutamate receptor 4 represents a promising antiparkinsonian approach in combination with <jats:sc>l<\/jats:sc>\u2010dopa, but it has not been demonstrated in primates.<\/jats:p><jats:p><jats:bold>Objective<\/jats:bold>: We studied whether a novel positive allosteric modulator of the metabotropic glutamate receptor 4, PXT002331 (foliglurax), could reduce parkinsonism in primate models.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold>: We assessed the therapeutic potential of PXT002331 in three models of MPTP\u2010induced parkinsonism in macaques. These models represent three different stages of disease evolution: early stage and advanced stage with and without <jats:sc>l<\/jats:sc>\u2010dopa\u2010induced dyskinesia.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold>: As an adjunct to <jats:sc>l<\/jats:sc>\u2010dopa, PXT002331 induced a robust and dose\u2010dependent reversal of parkinsonian motor symptoms in macaques, including bradykinesia, tremor, posture, and mobility. Moreover, PXT002331 strongly decreased dyskinesia severity, thus having therapeutic efficacy on both parkinsonian motor impairment and <jats:sc>l<\/jats:sc>\u2010dopa\u2010induced dyskinesia. PXT002331 brain penetration was also assessed using PET imaging in macaques, and pharmacodynamic analyses support target engagement in the therapeutic effects of PXT002331.<\/jats:p><jats:p><jats:bold>Conclusions<\/jats:bold>: This work provides a demonstration that a positive allosteric modulator of metabotropic glutamate receptor 4 can alleviate the motor symptoms of PD and the motor complications induced by <jats:sc>l<\/jats:sc>\u2010dopa in primates. PXT002331 is the first compound of its class to enter phase IIa clinical trials. \u00a9 2018 International Parkinson and Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.27462","type":"journal-article","created":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T07:20:09Z","timestamp":1537082409000},"page":"1619-1631","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["An m<scp>G<\/scp>lu4\u2010<scp>P<\/scp>ositive <scp>A<\/scp>llosteric <scp>M<\/scp>odulator <scp>A<\/scp>lleviates <scp>P<\/scp>arkinsonism in <scp>P<\/scp>rimates"],"prefix":"10.1002","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-7800","authenticated-orcid":false,"given":"Delphine","family":"Charvin","sequence":"first","affiliation":[{"name":"Prexton Therapeutics SA  1228 Plan\u2010les\u2010Ouates, Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Therese","family":"Di Paolo","sequence":"additional","affiliation":[{"name":"Neuroscience Research Unit CHU de Qu\u00e9bec, CHUL Pavillon and Faculty of Pharmacy Laval University  Quebec City Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Bezard","sequence":"additional","affiliation":[{"name":"Motac Neuroscience Ltd  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Gregoire","sequence":"additional","affiliation":[{"name":"Neuroscience Research Unit CHU de Qu\u00e9bec, CHUL Pavillon and Faculty of Pharmacy Laval University  Quebec City Quebec Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Takano","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Centre for Psychiatry Research, Department of Clinical Neuroscience  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Duvey","sequence":"additional","affiliation":[{"name":"Prexton Therapeutics SA  1228 Plan\u2010les\u2010Ouates, Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elsa","family":"Pioli","sequence":"additional","affiliation":[{"name":"Motac Neuroscience Ltd  Manchester United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christer","family":"Halldin","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Centre for Psychiatry Research, Department of Clinical Neuroscience  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Medori","sequence":"additional","affiliation":[{"name":"Prexton Therapeutics SA  1228 Plan\u2010les\u2010Ouates, Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Conquet","sequence":"additional","affiliation":[{"name":"Prexton Therapeutics SA  1228 Plan\u2010les\u2010Ouates, Geneva Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,14]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181a1d44c"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.06.001"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2015.07.002"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.25.12.1144"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_5.S1"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-381328-2.00002-X"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26362"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00882.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.29200\/acsmedchemrev-v51.ch3"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2012.679437"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9861(19990428)407:1<33::AID-CNE3>3.0.CO;2-G"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00429-016-1187-z"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.05.017"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.09-131789"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2009.06036.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1835724100"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1300.058"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.03.022"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.05.025"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1595-06.2006"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01515.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.111.187443"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.112.196063"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2014.07.008","article-title":"Therapeutic potential of metabotropic glutamate receptor 4\u2010positive allosteric modulator TAS\u20104 in rodent models of movement disorders","author":"Dube A","year":"2014","journal-title":"JNeurol Sci"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.6b00036"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00991"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-012-0016-z"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244093"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2013.01.009"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(10)84007-5"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.07.012"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23616"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25920"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130507"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01426.x"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1722-y"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2011.01.008"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-8-91"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.07.022"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3000130"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2010.07.011"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182887"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-018-1257-0"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25258"},{"key":"e_1_2_8_46_1","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0022-3565(24)34957-2","article-title":"Nicotinic acetylcholine receptor agonist SIB\u20101508Y improves cognitive functioning in chronic low\u2010dose MPTP\u2010treated monkeys","volume":"290","author":"Schneider JS","year":"1999","journal-title":"JPharmacol Exp Ther"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-0270(99)00184-3"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2014.05.007"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0169-328X(95)00321-I"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(01)00591-7"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a009308"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s007020050168"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4262-04.2005"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0566-3"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000050"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1112"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.066191"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2005.08.017"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052680"},{"key":"e_1_2_8_60_1","volume-title":"Pharmacology in Drug Discovery: Understanding Drug Response","author":"Kenakin T","year":"2012"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2014.245"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820070032005"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2006.06.008"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.135343"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(99)00067-2"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-018-1846-8"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.03.036"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4471-6503-3_13"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2014.11.001"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2012.651457"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70218-0"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2006.04124.x"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhp317"},{"key":"e_1_2_8_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(11)70038-4"},{"key":"e_1_2_8_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2471"},{"key":"e_1_2_8_76_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2011.10.005"},{"key":"e_1_2_8_77_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-56170-7_3"},{"key":"e_1_2_8_78_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.109.058768"},{"key":"e_1_2_8_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.03.027"},{"key":"e_1_2_8_80_1","first-page":"189","article-title":"Levodopa\u2010induced\u2010dyskinesias clinical features, incidence, risk factors, management and impact on quality of life","volume":"2","author":"Manson A","year":"2012","journal-title":"JParkinsons Dis"},{"issue":"3","key":"e_1_2_8_81_1","first-page":"CD004898","article-title":"Monoamine oxidase B inhibitors for early Parkinson's disease","author":"Macleod AD","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_82_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200932060-00004"},{"key":"e_1_2_8_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60683-8"},{"key":"e_1_2_8_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22060"},{"key":"e_1_2_8_85_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26078"},{"key":"e_1_2_8_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91411-8"},{"key":"e_1_2_8_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0196-0644(05)82473-4"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08081228"},{"key":"e_1_2_8_89_1","first-page":"344","article-title":"Mental side effects of amantadine therapy: its spectrum and characteristics in a normal population","volume":"42","author":"Flaherty JA","year":"1981","journal-title":"JClin Psychiatry"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S101569"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.2.226"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.70.6.734"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.0943"},{"key":"e_1_2_8_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26159"},{"key":"e_1_2_8_95_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.9.985"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/0006-8993(90)90069-N"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.051912"},{"key":"e_1_2_8_98_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25133"},{"key":"e_1_2_8_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2015.10.039"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20738"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2017.09.023"},{"key":"e_1_2_8_102_1","first-page":"1316","article-title":"Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans","volume":"29","author":"Naritomi Y","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_8_103_1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/S0090-9556(24)14938-0","article-title":"Prediction of human clearance of twenty\u2010nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half\u2010life approach and nonspecific binding to microsomes","volume":"27","author":"Obach RS","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_8_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-1931(00)00031-8"},{"key":"e_1_2_8_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2013.01.024"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.27462","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.27462","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T12:16:20Z","timestamp":1760962580000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.27462"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,14]]},"references-count":104,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/mds.27462"],"URL":"https:\/\/doi.org\/10.1002\/mds.27462","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,14]]},"assertion":[{"value":"2017-12-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}